What were the results of the ACCORD trial regarding glycemic control and CVD events in patients with type 2 diabetes mellitus?
The ACCORD trial recruited 10251 patients with a mean glycated hemoglobin of 8.1%. Participants were then randomized to receive intensive (glycated hemoglobin goal, <6.0%) or standard (goal, 7.0% 7.9%) therapy. The study was stopped earlier than planned because of an increase in all-cause mortality in the intensive therapy group with no difference in the numbers of fatal and nonfatal strokes.